Coronary artery disease (CAD) is one of the most common causes of death in South Africa and one of the most intensively managed chronic conditions in the private healthcare system. As a Chronic Disease List (CDL) condition, it carries specific medical aid obligations — and, in its procedural phases, some of the highest specialist shortfalls in private healthcare.
What Is Coronary Artery Disease?
CAD develops when atherosclerotic plaques build up in the coronary arteries, narrowing or blocking blood flow to the heart muscle. The spectrum ranges from stable angina (chest pain on exertion, managed with medication) to acute coronary syndrome (ACS) — which includes unstable angina and myocardial infarction (heart attack), both medical emergencies.
Severity staging for medical aid purposes: - Stable angina / silent ischaemia: Managed with oral medication; no procedural intervention required. - Stable angina with significant stenosis: PCI (percutaneous coronary intervention — angioplasty with stenting) indicated. - Multi-vessel or left main disease: CABG (coronary artery bypass grafting) considered. - ACS (STEMI/NSTEMI): Emergency PCI or medical thrombolysis.
CDL and PMB Coverage
Coronary artery disease is a Chronic Disease List (CDL) condition. This means:
- Your medical aid must provide a defined minimum benefit for CAD medications and management.
- You must register your condition with your scheme to access the CDL benefit.
- Registration is required once — you do not re-register annually.
- CDL medications (statins, beta-blockers, ACE inhibitors, antiplatelet agents) must be funded regardless of your medical savings account balance.
CAD is also covered under PMB for acute events (ACS, emergency PCI). Emergency interventions cannot be refused by the scheme.
Treatment Pathway
Chronic stable CAD (medical management): - Statin (atorvastatin or rosuvastatin) — reduces plaque progression and cardiovascular events - Beta-blocker (bisoprolol, carvedilol, metoprolol) — reduces cardiac workload and angina - ACE inhibitor (ramipril, perindopril) — reduces cardiac remodelling and cardiovascular risk - Antiplatelet (aspirin 75–100mg) — reduces thrombosis risk - Nitrate (isosorbide mononitrate or sublingual GTN) — for angina symptom relief
Post-ACS or post-PCI (dual antiplatelet therapy — DAPT): - Aspirin + clopidogrel or ticagrelor for 6–12 months post-stent - Duration depends on stent type and clinical risk
PCI procedure: - Day-case or overnight admission - Coronary angiogram + balloon angioplasty + drug-eluting stent insertion - Procedure and stent cost: R40,000–R100,000 (procedure alone, before specialist fees)
CABG: - Open-heart surgery using vein or arterial grafts to bypass stenosed coronary segments - Hospital stay: 5–10 days - Total event cost including ICU: R150,000–R350,000+ before specialist shortfall
Medication Costs
Estimated; SAHPRA SEP verification pending.
| Medication | Class | Estimated Monthly Cost |
|---|---|---|
| Atorvastatin | Statin | R200–R300 |
| Rosuvastatin | Statin | R300–R500 |
| Bisoprolol | Beta-blocker | R150–R250 |
| Ramipril / Perindopril | ACE inhibitor | R180–R250 |
| Aspirin (low-dose) | Antiplatelet | R25–R40 |
| Clopidogrel | P2Y12 antiplatelet | R600–R900 |
| Ticagrelor (Brilique) | P2Y12 antiplatelet | R1,000–R1,500 |
| Evolocumab (Repatha) | PCSK9 inhibitor | R4,000–R5,000 |
Note on PCSK9 inhibitors: evolocumab (Repatha) and alirocumab (Praluent) are injectable biologics used in patients with very high cardiovascular risk who cannot achieve target LDL on maximum-dose statins, or who are statin-intolerant. They require exceptional-needs authorisation and are not CDL-mandatory. Monthly cost is approximately 10–20× that of oral statins.
Annual Cost Estimates
| Scenario | Estimated Annual Cost |
|---|---|
| Stable CAD, medications only | R5,000 – R20,000 |
| PCI (angioplasty + stent) + post-procedure DAPT | R60,000 – R180,000 |
| CABG + ICU recovery | R180,000 – R350,000 |
| CABG + cardiac rehabilitation | R200,000 – R400,000 |
The Procedural Cost Gap: Where Gap Cover Is Most Critical
Oral medication for stable CAD costs R500–R2,000/month — well within CDL benefit structures. The financial risk in CAD is concentrated at the interventional event: PCI or CABG.
In SA private hospitals, cardiologists performing PCI commonly bill at 200–400% of medical aid tariff. On a procedure where the medical aid pays R40,000 at tariff, a cardiologist billing at 300% sends an account of R120,000 — leaving an R80,000 shortfall. The anaesthesiologist adds a further R10,000–R25,000 shortfall.
For CABG, the cardiothoracic surgeon, anaesthesiologist, perfusionist, and cardiologist all bill separately. Total specialist shortfall on CABG can reach R100,000–R250,000.
Gap cover absorbs these shortfalls up to its OPL (approximately R220,000/year). A straightforward PCI event is typically within the OPL. Complex CABG with ICU stay can challenge it.
Registering for the CDL Benefit
To access the CDL benefit for CAD, you need a formal diagnosis and a motivation from your treating physician (cardiologist or physician). Contact your scheme's chronic benefits department and ask for the CDL registration form. Required documents typically include:
- Completed scheme-specific CDL application form
- ICD-10 code I25.x
- Confirming clinical documents (ECG, stress test, coronary angiogram report, or cardiologist letter)
Once registered, your CDL medications are funded from a separate CDL benefit that does not deplete your MSA. This is a significant financial benefit — do not delay registration.
PCSK9 Inhibitors: Emerging High-Cost Therapy
For patients with familial hypercholesterolaemia (FH) or very high cardiovascular risk who cannot tolerate statins or cannot reach LDL targets on maximum-dose statin therapy, PCSK9 inhibitors (evolocumab/Repatha, alirocumab/Praluent) are guideline-recommended. Monthly cost in SA: approximately R4,000–R5,000. Most schemes require a formal exceptional-needs application with LDL levels, statin intolerance documentation, and FH confirmation.
Talk to Eldon
See which plans pay for coronary artery disease →
This page is general information about medical schemes. It is not medical advice: speak to a healthcare professional about your own treatment. Medical aid and gap cover advice is given by Eldon de Waal, a Supervised Representative of Approach Administration (FSP 23579).